This is a topic where the cost of intellectual dishonesty is high in both directions. The standard maneuvers — pretending the evidence is settled when it isn't, or pretending the children at the center of this are political pawns rather than real people with real distress — both fail. What follows is an attempt to describe the actual state of policy and evidence across five countries that have taken substantially different paths, with the kind of intellectual humility (Law 0) that the topic demands.

The medical model that dominated Western practice in the 2010s, often called the "Dutch protocol" after the Amsterdam clinic that developed it, involved psychological assessment of adolescents with gender dysphoria, puberty suppression with GnRH analogs starting around Tanner stage 2, cross-sex hormones starting around age sixteen, and surgery in adulthood. The model was developed for a specific clinical population — children with persistent, intense, long-standing gender dysphoria, typically beginning in early childhood, often male-to-female. As the model was exported internationally and as referral rates rose dramatically (especially among adolescent natal females, often with no prior history of dysphoria, and often with co-occurring conditions like autism, anxiety, depression, or recent social transition), the question arose whether the original evidence base actually supported the practice as it was now being applied.

Five countries have produced public answers to that question that are worth tracing.

The Netherlands developed the original protocol and continues to use it, though with increasing acknowledgment that the original cohort and the contemporary referral population differ substantially. Dutch researchers have published the original outcome studies that the rest of the field cited for two decades, and have also published more cautious recent statements about the limits of generalizing from that cohort.

The United Kingdom commissioned an independent review under Dr. Hilary Cass, a pediatrician, after concerns about the Tavistock Gender Identity Development Service (GIDS) accumulated. The Cass Review, published in final form in April 2024, concluded that the evidence base for puberty blockers and cross-sex hormones in adolescents was weak, that the assessment processes at GIDS had been inadequate, and that the model needed substantial reform. NHS England closed GIDS and restricted puberty blockers to research contexts. Hannah Barnes's book Time to Think documented the internal clinical concerns that preceded the review.

Sweden's Karolinska Institute, one of the most prestigious medical institutions in Europe, restricted hormonal interventions for minors to research settings in 2021, citing insufficient evidence. The Swedish National Board of Health and Welfare followed with national guidance in 2022 that took a similarly cautious position.

Finland's Council for Choices in Health Care (COHERE) issued guidelines in 2020 that prioritized psychological assessment and treatment of co-occurring conditions before medical intervention, and limited medical interventions to a small subset of cases with long-standing, persistent dysphoria.

The United States has moved in the opposite direction at the institutional level. WPATH's Standards of Care version 8 (2022) generally affirmed earlier and broader access to medical interventions for minors, while removing previous minimum age recommendations from some sections. Major US medical organizations (AAP, Endocrine Society) have affirmed gender-affirming care. At the political level, more than 20 US states have passed laws restricting or banning such care for minors as of 2024, and the legal status is in active flux. The 2024 US Supreme Court case United States v. Skrmetti will rule on the constitutionality of state bans.

The honest summary is that the European countries that have most carefully reviewed the evidence have moved toward greater caution, while US medical organizations and US state politics have polarized in opposite directions, producing a domestic landscape that does not map onto the international one. The Cass Review is the most thorough public document on the evidence to date, and its conclusion — that the evidence base is weaker than the prior consensus assumed — is not yet fully metabolized in American medical discourse.

For parents, the collective implications are real. This is a domain where what counts as standard of care varies by jurisdiction, where the evidence is contested by serious people on multiple sides, where the population presenting for care has changed substantially in the past decade, and where the political polarization makes calm conversation almost impossible. Law 4 (Plan) and Law 5 (Revise) both apply: the policies in place now will be revised, the evidence base is still being assembled, and parents facing the question with their own child are doing so inside a system that is itself uncertain.

What parents can reasonably ask for is: thorough assessment that takes time, treatment of co-occurring conditions before or alongside any gender-related intervention, honest discussion of evidence quality and uncertainty, conservative pacing where reversible interventions are tried first, and reassessment over months and years rather than weeks. These are not radical positions; they are roughly the European emerging consensus.

What should not be done — by any side — is pretend this is simple. The detransitioner literature is real, the persistence of gender dysphoria in some children is real, the suicidality concerns are real, the iatrogenic harm concerns are real, and the politicization of all of it is real. Holding all of these together without collapsing into any of them is what intellectual honesty requires.